13F HOLDINGS REPORT
ARCH Venture Management, LLC
Quarter ended Q2 2025 · Filed August 14, 2025 · Accession 0001012975-25-000444
Total Value
$299.1M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BEAM THERAPEUTICS INC. | BEAM | 4,540,132 | $77.2M | 25.82% |
| 2 | VIR BIOTECHNOLOGY INC. | VIR | 12,916,663 | $65.1M | 21.76% |
| 3 | MAZE THERAPEUTICS INC. | MAZE | 4,120,053 | $50.6M | 16.91% |
| 4 | RAPPORT THERAPEUTICS INC. | RAPP | 3,728,738 | $42.4M | 14.19% |
| 5 | VERVE THERAPEUTICS INC. | 92539P101 | 2,008,809 | $22.6M | 7.54% |
| 6 | LYELL IMMUNOPHARMA INC. | LYEL | 1,820,634 | $16.1M | 5.39% |
| 7 | ERASCA INC. | ERAS | 11,055,554 | $14.1M | 4.71% |
| 8 | GOSSAMER BIO INC. | GOSS | 8,055,916 | $9.9M | 3.31% |
| 9 | Q32 BIO INC. | QTTB | 320,482 | $477,518 | 0.16% |
| 10 | UNITY BIOTECHNOLOGY INC. | UNTCW | 1,004,817 | $385,950 | 0.13% |
| 11 | CERO THERAPEUTICS HOLDINGS INC. | CEROW | 22,389 | $215,606 | 0.07% |